Valsts: Malaizija
Valoda: angļu
Klimata pārmaiņas: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
ATORVASTATIN CALCIUM
THE ZYFAS MEDICAL CO.,
ATORVASTATIN CALCIUM
28'stablet Tablets; 30tablet Tablets
Dr. Reddy`s Laboratories Ltd.
180 - 480 mm PC - xxxx Folding size : 180 x 40 mm to <5 times ULN, treatment discontinuation should be considered. v If symptoms resolve and CK levels return to normal, then re-introduction of atorvastatin or introduction of an alternative statin may be considered at the lowest dose and with close monitoring. v Atorvastatin must be discontinued if clinically significant elevation of CK levels (> 10 times ULN) occur, or if rhabdomyolysis is diagnosed or suspected. _Increased risk of rhabdomyolysis_ Risk of rhabdomyolysis is increased when atorvastatin is administered concomitantly with certain medications that may increase the plasma concentration of atorvastatin such as potent inhibitors of CYP3A4 or transport proteins (eg. ciclosporine, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole , and HIV-protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc). The risk of myopathy may also be increased with the concomitant use of gemfibrozil and other fibric acid derivates, erythromycin, niacin and ezetimibe. If possible alternative (non-interacting) therapies should be considered instead of these medicinal products. _Concomitant treatment with other medicinal products_ Co-administration of strong CYP3A4 inhibitors (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc.) should be avoided if possible. In cases where co-administration of these medicinal products with atorvastatin cannot be avoided, lower starting and maximum doses of atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended. In patients taking telaprevir, concomitant use of atorvastatin should be avoided. The dose of atorvastatin should not exceed 40 mg daily when taking with boceprevir and close clinical monitoring is recommended. The concurrent u Izlasiet visu dokumentu